Trials / Completed
CompletedNCT06313268
Safety of Effivia®, a Bevacizumab Biosimilar
Post-marketing Safety of Effivia®, a Bevacizumab Biosimilar: Phase IV, Observational, Multicenter Clinical Study in Mexican Population
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 83 (actual)
- Sponsor
- Laboratorios Liomont · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a post-marketing observational study aimed to evaluated the safety profile of Effivia®, a biosimilar of bevacizumab, in mexican patients with different types of cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevacizumab Biosimilar MB02 | 5 mg/kg to 15 mg/kg in combination with chemotherapy. |
Timeline
- Start date
- 2022-08-11
- Primary completion
- 2024-04-17
- Completion
- 2024-09-02
- First posted
- 2024-03-15
- Last updated
- 2024-10-10
Locations
5 sites across 1 country: Mexico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06313268. Inclusion in this directory is not an endorsement.